Tag: 300-400

Treatment strategy for patients with relapsed/refractory classical Hodgkin lymphoma was written by Yoshida, Isao. And the article was included in Ketsueki Naika in 2021.Related Products of 16506-27-7 The following contents are mentioned in the article:

A review. Classical Hodgkin lymphoma (CHL) is a type of lymphoma that is sensitive to chemotherapy and can provide an R-stage solution in many cases. Single-center pre-examination study of combination treatment with bendamustine, nivolumab for patients who became refractory to treatment with nivolumab. It will be performed in consideration of the disease, organ function, and the drug packing used in the previous treatment, but if the reduction effect is obtained by the rescue chemotherapy, the self-implantation combined large-scale chemotherapeutic method (ASCT) is used as a remedy treatment. This review outlines the treatment of relapsed/refractory classical Hodgkin lymphoma with a focus on brentuximab vedotin and ΡD-1 antibodies, and the usefulness of autologous stem cell transplant in therapeutic cases. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Reduced bendamustine for elderly patients with follicular lymphoma was written by Masamoto, Yosuke;Shimura, Arika;Kurokawa, Mineo. And the article was included in Annals of Hematology in 2022.Application of 16506-27-7 The following contents are mentioned in the article:

As the outcome of follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin’s lymphoma, has been improved since the introduction of immunochemotherapy, non-lymphoma-related causes of death, including infections, have become increasingly important. Bendamustine is widely used as one of the key drugs of the standard therapy, and characterized by long-term lymphocytopenia as a frequent adverse event, rendering the patients especially vulnerable to various infections. In this study, authors aims to clarify the short-term outcome and toxicities of the reduced bendamustine. Patients underwent bendamustine treatment without dose reduction from the original plan. Elderly patients in this cohort showed promising outcomes with a similar rate of toxicities except for lymphocytopenia. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Application of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy was written by Landsburg, Daniel J.;Nasta, Sunita D.;Gerson, James N.;Svoboda, Jakub;Chong, Elise A.;Schuster, Stephen J.;Barta, Stefan K.;Robinson, Kyle W.;Hughes, Mitchell E.. And the article was included in Leukemia & Lymphoma in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Our study is also unique in reporting time-to clin. response. While clin. responses as defined in this anal. could only be achieved by patients who demonstrated defined clin. signs/symptoms at the start of PV-based therapy, the majority of those patients who achieved a clin. response and had a subsequent radiog. assessment also achieved a radiog. response, suggesting that clin. response, when detectable, may be an indicator of disease response in this patient population. In conclusion, patients with relapsed/refractory DLBCL/ HGBL treated at our center with PV, with or without concurrent rituximab and/or bendamustine, frequently achieved rapid and durable responses. These findings may inform clin. management as well as investigational study design for this patient population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model was written by Liang, Jun;Van Abbema, Anne;Balazs, Mercedesz;Barrett, Kathy;Berezhkovsky, Leo;Blair, Wade S.;Chang, Christine;Delarosa, Donnie;De Voss, Jason;Driscoll, Jim;Eigenbrot, Charles;Goodacre, Simon;Ghilardi, Nico;MacLeod, Calum;Johnson, Adam;Bir Kohli, Pawan;Lai, Yingjie;Lin, Zhonghua;Mantik, Priscilla;Menghrajani, Kapil;Nguyen, Hieu;Peng, Ivan;Sambrone, Amy;Shia, Steven;Smith, Jan;Sohn, Sue;Tsui, Vickie;Ultsch, Mark;Williams, Karen;Wu, Lawren C.;Yang, Wenqian;Zhang, Birong;Magnuson, Steven. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2017.HPLC of Formula: 1334411-79-8 The following contents are mentioned in the article:

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients. This study involved multiple reactions and reactants, such as 4-Bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine (cas: 1334411-79-8HPLC of Formula: 1334411-79-8).

4-Bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine (cas: 1334411-79-8) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.HPLC of Formula: 1334411-79-8

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Development, In Vitro and In Vivo Evaluation of Hydrogel Based System of Carboxymethyl Arabinoxylan for Controlled Delivery of Rabeprazole Sodium was written by Tulain, Ume Ruqia;Ahmad, Mahmood;Rashid, Ayesha. And the article was included in Polymer-Plastics Technology and Engineering in 2018.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

Present study deals with development of polymeric systems for rabeprazole sodium to accomplish a lingering therapeutic outcome. Carboxymethyl arabinoxylan exhibited variety of ideal characteristics for polymeric drug carrier. Free radical polymerization was successfully employed to prepare pH responsive polymeric network of carboxymethyl arabinoxylan with acrylic acid. FTIR, SEM, thermogravimetric anal. and X-ray diffraction verified the graft copolymerization Graft copolymers revealed highly pH responsive swelling, consequently drug release at intestinal pH. In vivo evaluation indicated improvement in relative bioavailability by exhibiting increase in Cmax of polymeric system and same oral dose of rabeprazole sodium were 103.71 ± 16.081 and 61.263 ± 5.37 ng/mL, resp. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Cyclometalated 2-Phenylimidazole Palladium Carbene Complexes in the Catalytic Suzuki-Miyaura Cross-Coupling Reaction was written by Micksch, Maik;Tenne, Mario;Strassner, Thomas. And the article was included in Organometallics in 2014.Electric Literature of C21H24N2 The following contents are mentioned in the article:

We present the syntheses of cyclometalated palladium C-N 2-phenylimidazole carbene complexes with different N-1 groups as well as different substituents at the C-2 Ph group of the cyclometalating imidazole. We investigated the influence of these substituents by comparing the catalytic performance of the complexes in the Suzuki-Miyaura cross-coupling reaction of aryl chlorides. We can show a strong dependence between the steric demand of the N-1 substituent of the cyclometalating imidazole and the catalytic activity in the cross-coupling reaction. The most active complex shows a wide substrate scope, where several aryl as well as benzyl chlorides could be coupled with different boronic acids in excellent yields using very low catalyst concentrations of 0.05 mol %. This study involved multiple reactions and reactants, such as 1-(2,6-Diisopropylphenyl)-2-phenyl-1H-imidazole (cas: 914306-50-6Electric Literature of C21H24N2).

1-(2,6-Diisopropylphenyl)-2-phenyl-1H-imidazole (cas: 914306-50-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Electric Literature of C21H24N2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Homoleptic tris-cyclometalated iridium(III) complexes with phenylimidazole ligands for highly efficient sky-blue OLEDs was written by Zhuang, Jinyong;Li, Wanfei;Wu, Weichen;Song, Minshun;Su, Wenming;Zhou, Ming;Cui, Zheng. And the article was included in New Journal of Chemistry in 2015.Application of 914306-50-6 The following contents are mentioned in the article:

As an extension of the authors’ previous study, three sky-blue homoleptic Ir(III) complexes 1-3 with F-free phenylimidazole ligands were synthesized and their photophys., electrochem. and thermal properties were studied. All the complexes showed high photoluminescence quantum yields ranging from 0.50 to 0.53. The introduction of a bulky iso-Pr group at the 2,6-position of N-Ph of the phenylimidazole ligands increases the quantum yield and the decomposition temperature of the IR(III) complexes. As the conjugated system of the ligand becomes larger, a very small bathochromic-shift of 1 nm was observed in complex 3 (475 nm) compared with complexes 1 (474 nm) and 2 (474 nm). All the OLED devices showed high current efficiencies of over 20 cd A^-1 at the luminance of 1000 cd m^-2. Devices incorporated with complexes 1-3 all showed longer lifetime in comparison with that of a FIrpic-based device. This study involved multiple reactions and reactants, such as 1-(2,6-Diisopropylphenyl)-2-phenyl-1H-imidazole (cas: 914306-50-6Application of 914306-50-6).

1-(2,6-Diisopropylphenyl)-2-phenyl-1H-imidazole (cas: 914306-50-6) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Application of 914306-50-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study was written by Wang, Xiao-Xiao;Gao, Yan;Jin, Jie;Cao, Jun-Ning;Feng, Ji-Feng;Wang, Hua-Qing;Zhang, Hui-Lai;Cai, Qing-Qing;Li, Zhi-Ming;Jiang, Wen-Qi;Huang, Hui-Qiang;on behalf of the Lymphoma Committee, Chinese Anti-Cancer Association. And the article was included in Annals of Hematology in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

This study aimed to identify the maximum-tolerated dose (MTD) of cyclophosphamide when combined with bortezomib and fludarabine (B-FC) in a phase 1b trial, and to assess the efficacy and safety of this combination in a phase 2 trial in patients with relapsed or refractory MCL (rrMCL). Forty patients were enrolled between Apr. 8, 2011, and Oct. 10, 2015. The MTD of cyclophosphamide was identified to be 250 mg/m² days 1-2. At a median follow-up of 31.6 mo (13.5-47.4), among 32 patients in phase 2, 10 (31%) had a complete response and 13 (41%) had a partial response. The median progression-free survival was 21 mo (95% CI 7.3-34.7), and the median overall survival was 32.4 mo (95% CI 17.8-47.0). Grade 3-4 hematol. AEs included neutropenia (27%) and thrombocytopenia (39%). The B-FC regimen has satisfactory responses and manageable toxicities in rrMCL patients (ClinicalTrials.gov NCT01322776). This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Commentary: post-transplantation cyclophosphamide uniquely restrains alloreactive CD4+ T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation was written by Stokes, Jessica;Simpson, Richard J.;Katsanis, Emmanuel. And the article was included in Frontiers in Immunology in 2022.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Herein authors investigated whether post-transplant cyclophosphamide (PT-CY) is unique in protecting against graft-vs.-host disease (GvHD) by comparing it to multiple other ′′optimally dosed′â€?chemotherapeutics. They concluded that PT-CY was superior to all other agents in ameliorating both clin. and histopathol. GvHD. It discuss about post-transplantation cyclophosphamide which uniquely restrains alloreactive CD4+ T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation. Authors discuss on the use of post-transplant bendamustine (PT-BEN) as an alternative agent that could replace PT-CY. They demonstrated that PT-BEN was equally effective in preventing early GvHD and protecting against late GvHD, while enabling superior graft-vs.-leukemia (GvL), when compared to PT- CY in murine haploidentical bone marrow transplantation (haplo-BMT). This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis was written by Khurana, Arushi;Dalland, Joanna C.;Young, Jason R.;Inwards, David J.;Paludo, Jonas. And the article was included in American Journal of Hematology in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

The ZUMA-2 trial, however, excluded patients with a possible requirement for urgent therapy due to ongoing or impending oncol. emergency (eg, tumor mass effect, tumor lysis syndrome), involvement of the central nervous system and required patients to be exposed to a Bruton tyrosine kinase (BTK) inhibitor. Interim PET/CT after three cycles of bendamustine and rituximab, showed a significant improvement in lymphadenopathy and skeletal lesions, however, with new lesions in the nasopharynx and right chest wall. The patient underwent brexu-cel therapy after lymphodepletion chemo but his course was complicated by cytokine release syndrome (CRS) on day +1 with a peak grade of one based on the ASTCT 2019 grading. This is the first report of a brexu-cel for MCL-associated NL and blastoid variant with complete remission at day +60 without added neurotoxicity. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem